GlassScriptPhysician profile
Elliot J Ginchansky
NPI 1962401471
$2,465.32
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,913 · 2020: $359 · 2021: $46.62 · 2022: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.78 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $392.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $302.99 | 2019-2020 | |
| Sanofi Pasteur INC. | $229.07 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $203.55 | 2019-2022 | |
| Kaleo, INC. | $192.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $191.86 | 2019-2020 | |
| Covis Pharma Gmbh | $84.11 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $69.54 | 2019 | |
| Optinose US, INC. | $65.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.24 | 2020-2021 | |
| Alk-Abello, INC | $27.89 | 2019 | |
| Shire North American Group INC | $17.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2020 | |
| Greer Laboratories, INC. | $16.34 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $16.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Ginchansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.